| Literature DB >> 35536157 |
Joel Häfliger1, Olga O Sokolova1, Madina Lenz1, Constantin G Daniliuc1, Ryan Gilmour1.
Abstract
The success of saturated, fluorinated heterocycles in contemporary drug discovery provides a stimulus for creative endeavor in main group catalysis. Motivated by the ubiquity of isochromans across the bioactive small molecule spectrum, the prominence of the anomeric effect in regulating conformation, and the metabolic lability of the benzylic position, iodine(I)/iodine(III) catalysis has been leveraged for the stereocontrolled generation of selectively fluorinated analogs. To augment the current arsenal of fluorocyclization reactions involving carboxylic acid derivatives, the reaction of readily accessible 2-vinyl benzaldehydes is disclosed (up to >95 : 05 d.r. and 97 : 03 e.r.). Key stereoelectronic interactions manifest themselves in the X-ray crystal structures of the products, thereby validating the [CH2 -CHF] fragment as a stereoelectronic mimic of the [O-CH(OR)] acetal motif.Entities:
Keywords: Fluorination; Heterocycles; Hypervalent Iodine; Isosteres; Stereoelectronic Effects
Mesh:
Substances:
Year: 2022 PMID: 35536157 PMCID: PMC9401867 DOI: 10.1002/anie.202205277
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 16.823
Figure 1Bioactive isochromans and stereoelectronic mimicry and bioisostere design.
Scheme 1An II/IIII catalysis route to fluorinated isochroman isosteres.
Reaction optimization.[a]
|
| |||||
|---|---|---|---|---|---|
|
Entry |
Solvent |
Amine:HF |
Cat. |
MeOH [equiv] |
Yield [%][b] |
|
1 |
CHCl3 |
1 : 4.5 |
C1 |
2.5 |
65 |
|
2 |
CHCl3 |
1 : 4.5 |
C2 |
2.5 |
60 |
|
3 |
CHCl3 |
1 : 4.5 |
C3 |
2.5 |
46 |
|
4 |
CHCl3 |
1 : 4.5 |
C1 |
2.0 |
71 |
|
5 |
CHCl3 |
1 : 4.5 |
C1 |
1.5 |
69 |
|
6 |
CHCl3 |
1 : 4.0 |
C1 |
2.0 |
55 |
|
7 |
CHCl3 |
1 : 5.0 |
C1 |
2.0 |
46 |
|
8 |
DCM |
1 : 4.5 |
C1 |
2.0 |
57 |
|
9 |
DCE |
1 : 4.5 |
C1 |
2.0 |
56 |
|
10 |
MeCN |
1 : 4.5 |
C1 |
2.0 |
49 |
|
11[c] |
CHCl3 |
1 : 4.5 |
C1 |
2.0 |
78 |
|
12[d] |
CHCl3 |
1 : 4.5 |
C1 |
2.0 |
76 |
|
13[c,d] |
CHCl3 |
1 : 4.5 |
C1 |
2.0 |
85 (72) |
|
14 |
CHCl3 |
1 : 4.5 |
– |
2.0 |
– |
|
15 |
CHCl3 |
1 : 4.5 |
C1 |
– |
– |
|
16[e] |
CHCl3 |
1 : 4.5 |
C1 |
2.0 |
– |
[a] Standard reaction conditions: 1 a (0.2 mmol), Selectfluor® (1.5 equiv), amine⋅HF source prepared from NEt3⋅3 HF and Olah's reagent (0.5 mL), solvent (0.5 mL), catalyst (20 mol %), MeOH (0.4 mmol), 24 h, rt. [b] Determined by 19F NMR using ethyl 2‐fluoroacetate as internal standard (d.r.≥85 : 15). Combined yield. Combined isolated yield in parentheses. [c] Amine⋅HF mixture prepared with pyridine and Olah's reagent. [d] Amine⋅HF source (1.0 mL), solvent (1.0 mL). [e] No Selectfluor® was added.
Scheme 2Top: Scope for the fluorocyclization of 2‐vinylbenzaldehydes 1 to the corresponding anti‐4‐fluoro‐1‐methoxyisochromanes 2. Combined NMR yields are reported with isolated yields of the major isomer indicated in parentheses. Method A: 2‐Vinylbenzaldehyde 1 (0.4 mmol), C1 (20 mol %), CHCl3 (2.0 mL), Py⋅HF 1 : 4.5 (2.0 mL), MeOH (0.8 mmol) and Selectfluor® (0.6 mmol), 24 h, room temperature. Bottom: Scope for the fluorocyclization of 5‐chloro‐2‐vinylbenzaldehyde 1 j to the corresponding anti‐4‐fluoro‐1‐alkoxyisochromans 3–12. The reported yields are combined NMR yields, isolated yields of the major isomer in parentheses. NB: For secondary alcohols, improved yields are observed by adding three equivalents of the corresponding alcohols. [a] Py⋅HF 1 : 4.0 (2.0 mL) was used. [b] Combined NMR yield of diastereoisomers.
Figure 2X‐ray structural analysis of fluoroisochroman 2 a.
Enantioselective reaction optimization.[a]
|
| |||||
|---|---|---|---|---|---|
|
Entry |
Solvent |
R1 |
R2 |
Yield [%][b] |
|
|
1 |
CHCl3 |
OMe |
Me |
61 |
61 : 39 |
|
2 |
CHCl3 |
OMe |
Et |
51 |
59 : 41 |
|
3 |
CHCl3 |
OMe |
Bn |
40 |
56 : 44 |
|
4 |
CHCl3 |
NMe2 |
Me |
57 |
63 : 37 |
|
5 |
CHCl3 |
N( |
Me |
32 |
67 : 23 |
|
6 |
MeCN |
N( |
Me |
54 |
81 : 19 |
|
7 |
MTBE |
N( |
Me |
29 |
83 : 17 |
|
8 |
MeCN : MTBE 1 : 1 |
N( |
Me |
64 |
88 : 12 |
|
9 |
MeCN : MTBE 2 : 3 |
N( |
Me |
62 |
90 : 10 |
|
10c |
MeCN : MTBE 2 : 3 |
N( |
Me |
66 (51) |
90 : 10 |
[a] Standard reaction conditions: 1 a (0.2 mmol), Selectfluor® (1.5 equiv), amine⋅HF source prepared from pyridine and Olah's reagent (1.0 mL), solvent (1.0 mL), catalyst (20 mol %), MeOH (0.4 mmol), 24 h, rt. [b] Determined by 19F NMR using ethyl 2‐fluoroacetate as internal standard. Combined yield. Isolated yield of the major diastereoisomer in parentheses. [c] Solvent stored over molecular sieves.
Scheme 3Left: Scope for the fluorocyclization of 2‐vinylbenzaldehydes 1 to the corresponding anti‐4‐fluoro‐1‐methoxyisochromanes 2. The reported yields are combined NMR yields, isolated yields of the major isomer in parentheses. e.r. of the major diastereoisomer was determined by HPLC analysis and the d.r. was determined by 19F NMR analysis of the crude reaction mixture. Method B: 2‐Vinylbenzaldehyde 1 (0.2 mmol), C4 (20 mol %), MTBE/MeCN 3 : 2 (1.0 mL), Py⋅HF 1 : 4.0 (1.0 mL), MeOH (0.4 mmol) and Selectfluor® (0.3 mmol), 24 h, room temperature. Method C: Py⋅HF 1 : 4.5 (1.0 mL) was used. Method D: Py⋅HF 1 : 5.0 (1.0 mL) was used. [a] After recrystallization. [b] The reaction time was increased to 48 h. Right: The X‐ray crystal structure of compound (1R,4S)‐2 n (CCDC 2162684).
Figure 3A postulated induction model to account for the formation of the (S)‐configured fluorine center.
Scheme 4Derivatization of fluoroisochroman 2 a. Conditions: a) A (2.0 equiv), TMSOTf (1.0 equiv), CH2Cl2 (0.2 M), 0 °C, 2 h. syn‐13 (48 %), anti‐13 (42 %). b) Allyl‐TMS (2.0 equiv), TMSOTf (1.0 equiv), CH2Cl2 (0.2 M), 0 °C, 2 h. Major‐14 (55 %), minor‐14 (34 %). c) 2,2′‐Bipy (3.0 equiv), TMSOTf (2.0 equiv), CH2Cl2 (0.2 M), 0 °C, 45 min., then VinylOTMS (1.05 equiv), DCM (0.2 M), 0 °C, 21 h. d) NaBH4 (10.0 equiv), MeOH, 0 °C, 1.5 h. 15 (71 % over 2 steps, d.r. 77 : 23). e) MsCl (1.05 equiv), DIPEA (1.1 equiv), CH2Cl2, 0 °C to rt, 1.5 h. 16 (95 %, d.r. 77 : 23). f) B (1.1 equiv), DIPEA (1.4 equiv), ethylene glycol, 100 °C, 19 h. Anti‐17 (25 %), syn‐17 (12 %, d.r. 90 : 10).